MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating Allakos (Nasdaq: ALLK) for possible breaches of fiduciary duty and other violations of law in its transaction with Concentra.

President Donald Trump’s exemption of pharmaceuticals from the “reciprocal” tariffs he announced Wednesday limited the declines of biopharma stocks as financial markets tanked late last week ...

Allakos Inc. (NASDAQ: ALLK)'s sale to Concentra Biosciences, LLC for $0.33 in cash per share. If you are an Allakos shareholder, click here to learn more about your rights and options .

— We have everything you need: full data on over 800 000 bonds, 80 000 stocks, 116 000 ETF & Funds; powerful bond screener; over 350 pricing sources among stock exchanges & OTC market; ratings & ...

Today, a brief rundown of news involving Sarepta Therapeutics, Novartis and Allakos, as well as updates from CSL Behring and Roche that you may have missed.

SAN CARLOS, CA – Allakos Inc (NASDAQ:ALLK)., a biopharmaceutical company with a market capitalization of $22.34 million, has received notification from The Nasdaq Stock Market LLC that it no longer ...

Overview: Allakos Inc. is a clinical-stage biotechnology company focused on developing therapeutics targeting immunomodulatory receptors on immune effector cells for allergy, inflammatory ...

SAN CARLOS, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- Allakos Inc. (“Allakos”) (Nasdaq: ALLK), a biotechnology company that has been developing antibodies for the treatment of allergic, inflammatory ...